ProFactor Pharma

About:

ProFactor Pharma provides commercialise and supply recombinant blood factors for the treatment of haemophilia.

Website: http://profactorpharma.com/

Top Investors: Scottish Enterprise, Ingenza, Scottish Investment Bank, Kelvin Capital, Lancaster Capital

Description:

Haemophilia is an X-linked genetic disease associated with the dysfunction of the biological cascade leading to blood clotting. Coagulation factors are vital to the functioning of the mechanism that the human body uses to protect and repair itself from physical injury, by the formation of blood clots to seal ruptured blood vessels. Haemophilia patients have a reduced capacity to stop bleeding and are prone to bleeding internally, into joints and organs, and often require hospitalisation 3-4 times per year. Without proper treatment, haemophiliacs typically die from organ failure in their teens.